Advertisement

JDRF Perspective: Bridging the Gap—Translational Research to Prevent Progression of Diabetic Nephropathy

      Summary

      For those with type 1 diabetes (T1D), the diagnosis of diabetic nephropathy predicts a significant negative impact on quality of life and mortality risk. Diabetic nephropathy is a huge component of the potential cost of diabetes both to the individual and society. For this reason, JDRF and others have prioritized programs aimed to advance our understanding of diabetic nephropathy and translate findings to benefit patients with T1D. Although the current standard of care has reduced the incidence of diabetic nephropathy, a significant proportion of those with T1D are still at risk for declining renal function and progression to end-stage renal disease. Carefully directed research is needed to discover and translate novel targets and biomarkers for diabetic nephropathy to improve the prognosis and outlook for those with T1D and at risk for end-stage renal disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nathan D.M.
        • Zinman B.
        • Cleary P.A.
        • Backlund J.Y.
        • Genuth S.
        • et al.
        • DCCT/EDIC Research Group
        Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).
        Arch Intern Med. 2009; 169: 1307-1316
        • Orchard T.J.
        • Secrest A.M.
        • Miller R.G.
        • Costacou T.
        In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.
        Diabetologia. 2010; 53: 2312-2319
        • de Boer I.H.
        • Sun W.
        • Cleary P.A.
        • Lachin J.M.
        • Molitch M.E.
        • et al.
        • DCCT/EDIC Research Group
        Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.
        N Engl J Med. 2011; 365: 2366-2376
        • Rosolowsky E.T.
        • Skupien J.
        • Smiles A.M.
        • Niewczas M.A.
        • Roshan B.
        • Stanton R.
        • et al.
        Risk of ESRD in type 1 diabetes remains high in spite of renoprotection.
        J Am Soc Nephrol. 2011; 22: 545-553
        • Krolewski A.S.
        • Bonventre J.V.
        High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.
        Semin Nephrol. 2012; 32: 407-414
        • Ahola A.J.
        • Saraheimo M.
        • Forsblom C.
        • Hietala K.
        • Sintonen H.
        • et al.
        • FinnDiane Study Group
        Health-related quality of life in patients with type 1 diabetes—association with diabetic complications (the FinnDiane Study).
        Nephrol Dial Transplant. 2010; 25: 1903-1908
        • Insel R.A.
        • Deecher D.C.
        • Bewer J.
        JDRF mission, strategy, and priorities.
        Diabetes. 2012; 61: 30-35
        • JDRF Research
        (Referenced July 30, 2012)
        • Nierras C.R.
        • Atkinson M.A.
        • Goldstein R.A.
        The Juvenile Diabetes Research Foundation at forty: updates of research in type 1 diabetes.
        Diabetes. 2010; 59: 1575-1577
        • Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
        Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
        JAMA. 2003; 290: 2159-2167
        • Zhang L.
        • Krzentowski G.
        • Albert A.
        • Lefebvre P.J.
        Factors predictive of nephropathy in DCCT type 1 diabetic patients with good or poor metabolic control.
        Diabet Med. 2003; 20: 580-585
        • Nordwall M.
        • Arnqvist H.J.
        • Bojestig M.
        • Ludvigsson J.
        Good glycemic control remains crucial in prevention of late diabetic complications—the Linkoping Diabetes Complications Study.
        Pediatr Diabetes. 2009; 10: 168-176
        • Anderson B.J.
        • McKay S.V.
        Barriers to glycemic control in youth with type 1 diabetes and type 2 diabetes.
        Pediatr Diabetes. 2011; 12: 197-205
        • Lancaster B.M.
        • Pfeffer B.
        • McElligott M.
        • Ferguson A.T.
        • Miller M.
        • Wallace D.
        • et al.
        Assessing treatment barriers in young adults with type 1 diabetes.
        Diabetes Res Clin Pract. 2010; 90: 243-249
        • Freeman J.S.
        Insulin analog therapy: improving the match with physiologic insulin secretion.
        J Am Osteopath Assoc. 2009; 109: 26-36
        • Kowalski A.J.
        Can we really close the loop and how soon?.
        Diabetes Technol Ther. 2009; 11: S113-S119
        • Kowalski A.
        • Lum J.W.
        Juvenile diabetes research foundation artificial pancreas consortium update.
        J Diabetes Sci Technol. 2009; 3: 1224-1226
        • Russell S.J.
        • El-Khatib F.H.
        • Nathan D.M.
        • Damiano E.R.
        Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
        J Diabetes Sci Technol. 2010; 4: 1288-1304
        • El-Khatib F.H.
        • Russell S.J.
        • Nathan D.M.
        • Sutherlin R.G.
        • Damiano E.R.
        A bihormonal closed-loop artificial pancreas for type 1 diabetes.
        Sci Transl Med. 2010; 2 (27ra27)
        • Castle J.R.
        • Engle J.M.
        • El Youssef J.
        • Massoud R.G.
        • Yuen K.C.
        • Kagan R.
        • et al.
        Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.
        Diabetes Care. 2010; 33: 1282-1287
        • Roth J.D.
        • Maier H.
        • Chen S.
        • Roland B.L.
        Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications.
        Arch Neurol. 2009; 66: 306-310
        • Ahren B.
        The future of incretin-based therapy: novel avenues—novel targets.
        Diabetes Obes Metab. 2011; 13: 158-166
        • Mauer M.
        • Zinman B.
        • Gardiner R.
        • Suissa S.
        • Sinaiko A.
        • Strand T.
        • et al.
        Renal and retinal effects of enalapril and losartan in type 1 diabetes.
        N Engl J Med. 2009; 361: 40-51
        • Burney B.O.
        • Kalaitzidis R.G.
        • Bakris G.L.
        Novel therapies of diabetic nephropathy.
        Curr Opin Nephrol Hypertens. 2009; 18: 107-111
        • Cortinovis M.
        • Cattaneo D.
        • Perico N.
        • Remuzzi G.
        Investigational drugs for diabetic nephropathy.
        Expert Opin Investig Drugs. 2008; 17: 1487-1500
        • Tuttle K.R.
        • Bakris G.L.
        • Toto R.D.
        • McGill J.B.
        • Hu K.
        • Anderson P.W.
        The effect of ruboxistaurin on nephropathy in type 2 diabetes.
        Diabetes Care. 2005; 28: 2686-2690
        • Tuttle K.R.
        • McGill J.B.
        • Haney D.J.
        • Lin T.E.
        • Anderson P.W.
        • PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Groups
        Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.
        Clin J Am Soc Nephrol. 2007; 2: 631-636
        • Blouza S.
        • Dakhli S.
        • Abid H.
        • Aissaoui M.
        • Ardhaoui I.
        • Ben Abdallah N.
        • et al.
        Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy.
        J Nephrol. 2010; 23: 415-424
        • Mueller P.W.
        • Rogus J.J.
        • Cleary P.A.
        • Zhao Y.
        • Smiles A.M.
        • Steffes M.W.
        • et al.
        Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes.
        J Am Soc Nephrol. 2006; 17: 1782-1790
        • Sandholm N.
        • McKnight A.J.
        • Salem R.M.
        • Brennan E.
        • Forsblom C.
        • McKay G.
        • et al.
        New genetic loci identified in a genome-wide meta-analysis of diabetic nephropathy.
        ADA, San Diego, CA2011
        • Pezzolesi M.G.
        • Katavetin P.
        • Kure M.
        • Poznik G.D.
        • Skupien J.
        • Mychaleckyj J.C.
        • et al.
        Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy.
        Diabetes. 2009; 58: 2698-2702
        • Pezzolesi M.G.
        • Skupien J.
        • Mychaleckyj J.C.
        • Warram J.H.
        • Krolewski A.S.
        Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD collection.
        Semin Nephrol. 2010; 30: 126-140
        • Alpers C.E.
        • Hudkins K.L.
        Mouse models of diabetic nephropathy.
        Curr Opin Nephrol Hypertens. 2011; 20: 278-284
        • Brosius 3rd, F.C.
        • Alpers C.E.
        • Bottinger E.P.
        • Breyer M.D.
        • Coffman T.M.
        • Gurley S.B.
        • et al.
        Mouse models of diabetic nephropathy.
        J Am Soc Nephrol. 2009; 20: 2503-2512
        • Tramonti G.
        • Kanwar Y.S.
        Tubular biomarkers to assess progression of diabetic nephropathy.
        Kidney Int. 2011; 79: 1042-1044
        • Cherney D.Z.
        • Sochett E.B.
        • Dekker M.G.
        • Perkins B.A.
        Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated type 1 diabetes.
        Diabet Med. 2010; 27: 1358-1365
        • Hovind P.
        • Rossing P.
        • Johnson R.J.
        • Parving H.H.
        Serum uric acid as a new player in the development of diabetic nephropathy.
        J Ren Nutr. 2011; 21: 124-127
        • Hovind P.
        • Rossing P.
        • Tarnow L.
        • Johnson R.J.
        • Parving H.H.
        Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.
        Diabetes. 2009; 58: 1668-1671
        • Ficociello L.H.
        • Rosolowsky E.T.
        • Niewczas M.A.
        • Maselli N.J.
        • Weinberg J.M.
        • Aschengrau A.
        • et al.
        High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.
        Diabetes Care. 2010; 33: 1337-1343
        • Rosolowsky E.T.
        • Ficociello L.H.
        • Maselli N.J.
        • Niewczas M.A.
        • Binns A.L.
        • Roshan B.
        • et al.
        High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.
        Clin J Am Soc Nephrol. 2008; 3: 706-713
        • Chudleigh R.A.
        • Ollerton R.L.
        • Dunseath G.
        • Peter R.
        • Harvey J.N.
        • Luzio S.
        • et al.
        Use of cystatin C-based estimations of glomerular filtration rate in patients with type 2 diabetes.
        Diabetologia. 2009; 52: 1274-1278
        • Perkins B.A.
        • Krolewski A.S.
        Early nephropathy in type 1 diabetes: the importance of early renal function decline.
        Curr Opin Nephrol Hypertens. 2009; 18: 233-240
        • Gosmanov A.R.
        • Gosmanova E.O.
        Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the DCCT/EDIC cohort.
        Arch Intern Med. 2011; 171: 1596
        • Altar C.A.
        The Biomarkers Consortium: on the critical path of drug discovery.
        Clin Pharmacol Ther. 2008; 83: 361-364
        • IMI-SUMMIT EU
        (Accessed July 30, 2012)